Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 8, 2008, Pages 1879-1883

  Akhondzadeh, Shahin ^a   Malek Hosseini, Mojgan ^a   Ghoreishi, Aboulfazl ^b   Raznahan, Maedeh ^c   Rezazadeh, Shams Ali ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Institute of Medicinal Plants Iran   (Iran)

Author keywords

5HT2A 2C antagonist; Ritanserin; Schizophrenia

Indexed keywords

RISPERIDONE; RITANSERIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INCREASED APPETITE; INSOMNIA; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; TREATMENT RESPONSE; URINE RETENTION; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOPATHOLOGY; RETROSPECTIVE STUDIES; RISPERIDONE; RITANSERIN; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 56449125612     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.08.020     Document Type: Article

References (27)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (2000), American Psychiatric Association, Washington, DC Text Revision
2. Akhondzadeh S. Hippocampal synaptic plasticity and cognition. J Clin Pharm Ther 24 (1999) 241-248
3. Akhondzadeh S., Mohammadi M.R., Amini-Nooshabadi H., and Davari Ashtiani R. Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. J Clin Pharm Ther 24 (1999) 49-52
4. Akhondzadeh S. The 5-HT hypothesis of schizophrenia. IDRUGS 4 (2001) 295-300
5. Akhondzadeh S., Mahajeri H., Mohammadi M.R., and Amini H. Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute episodes of mania: a double blind and placebo controlled trial. BMC Psychiatry 19: 3 1 (2003) 7
6. Akhondzadeh S. Pharmacotherapy of schizophrenia: the past, present and future. Curr Drug Ther 1 (2006) 1-7
7. Alvarez E., Ciudad A., Olivares J.M., Bousoňo M., and Gǒomez J.C. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol 26 (2006) 238-249
8. Bersani G., Grispini A., and Mariani S. Neuroleptic-induced extrapyramidal side effects: clinical perspective with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 40 (1986) 492-499
9. Buckley P.F., and Stahl S.M. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?. Acta Psychiatr Scand 115 (2007) 93-100
10. Ceulemans D.L., Gelders Y.G., Hoppenbrouwers M.L., Reyntjens A.J., and Janssen P.A. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85 (1985) 329-332
11. Chouinard G., Ross-Chouinard A., Annables L., and Jones B.D. Extrapyramidal symptoms rating scale (abstract). Can J Neurol Sci 7 (1980) 233
12. Duinkerke S.J., Botter P.A., Jansen A.A., Dongen P.A.V., Haaften A.J.V., Boom A.J., Laarhoven J.H.V., and Busard H.L. Ritanserin, a selective 5- HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo controlled double-blind trial. Br J Psychiatry 163 (1993) 451-455
13. Den Boer J.A., Vahlne J.O., Post P., Heck A.H., Daubenton F., and Olbrich R. Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Hum Psychopharmaco l5 (2000) 179-189
14. Erhart S.M., Marder S.R., and Carpenter W.T. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull 32 (2006) 234-237
15. Goudie A.J., Cooper G.D., Cole J.C., and Sumnall H.R. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. J Psychopharmacol 21 (2007) 179-190
16. Javitt D.C. Management of negative symptoms of schizophrenia. Curr Psychiatry Rep 3 (2001) 413-417
17. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale for schizophrenia. Schizophrenia Bull 13 (1987) 261-276
18. Mohammadi M.R., and Akhondzadeh S. Schizophrenia: etiology and pharmacotherapy. IDrugs 4 (2001) 1167-1172
19. Miller C.H., Fleischhacker W.W., and Ehrman H. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull 26 (1990) 373-376
20. Miller C.H., Hummer M., Pscha R., and Fleischhacker W.W. The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: case reports. Prog Neuropsychopharmacol Biol Psychiatry 16 (1992) 247-251
21. Möller H.J. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 17 (2003) 793-823
22. Möller H.J. Non-neuroleptic approaches to treating negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 254 (2004) 108-116
23. Murphy B.P., Chung Y.C., Park T.W., and McGorry P.D. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 88 (2006) 5-25
24. Shadach E., Gaisler I., Schiller D., and Weiner I. The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin. Neuropsychopharmacology 23 (2000) 151-161
25. Tattan T.M., and Creed F.H. Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 27 (2001) 149-155
26. Wiesel F.A., Nordström A.L., Farde L., and Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114 (1994) 31-38
27. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects (2000). http://www.wma.net Available at: http://www.wma.net